Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alzecure Pharma AB
Headquarters: Huddinge, Sweden
Website: https://www.alzecurepharma....
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Martin Jönsson
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -9.06
Exchange/Ticker 1: SSE:ALZCUR
Exchange/Ticker 2: N/A
Latest Market Cap: $28,012,101
BioCentury | Oct 5, 2021
Product Development
Lengthy TRPV1 pipeline now backed by Nobel prize
The now Nobel Prize-winning discovery of TRPV1 has led to a well-stocked therapeutic pipeline
BioCentury | Aug 13, 2021
Product Development
Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt
Plus Vyne, AlzeCure and Jazz
BioCentury | Jul 30, 2021
Translation in Brief
Stanford, Tempus unveil high-throughput screening platforms; plus Blueprint, Editas, Prothena, AlzeCure and more
BioCentury’s roundup of translational news
BioCentury | Feb 17, 2021
Management Tracks
Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers
Regenerative medicine company Athersys Inc. (NASDAQ:ATHX) said Chairman and CEO Gil Van Bokkelen has stepped down. While the company searches for a successor, President and COO William Lehmann will be
BioCentury | Nov 6, 2018
Finance
Advancing AlzeCure
AlzeCure plans to bring its Alzheimer’s programs to the clinic with $22M IPO
Items per page:
1 - 6 of 6